PMID- 26192308
OWN - NLM
STAT- MEDLINE
DCOM- 20160425
LR  - 20181202
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 7
DP  - 2015
TI  - A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for 
      Castration-Resistant Prostate Cancer.
PG  - e0133803
LID - 10.1371/journal.pone.0133803 [doi]
LID - e0133803
AB  - BACKGROUND: Endothelin A (ET-A) receptor antagonists including zibotentan and 
      atrasentan, have been suggested as a treatment for castration-resistant prostate 
      cancer (CRPC). Our aim was to conduct a meta-analysis and indirect comparison to 
      assess the efficacy and safety of ET-A receptor antagonists for treatment of 
      CRPC. METHODS: We systematically searched PubMed, EMBASE, the Cochrane Library, 
      and Web of Science from inception to November 2014 to identify randomized 
      controlled trials (RCTs) which assessed ET-A receptor antagonists for treatment 
      of CRPC. Meta-analysis was conducted by STATA version 12.0 software. RESULTS: 
      Eight RCTs were identified, involving 6,065 patients. The results of direct 
      comparison showed that compared with placebo, there was no statistically 
      significant difference in the improvement of progression-free survival (PFS), 
      overall survival (OS), time to disease progression (TTP), and total adverse 
      events (AEs) with ET-A receptor antagonist treatment for CRPC. The results of 
      ET-A receptor antagonists plus docetaxel versus docetaxel alone were similar. The 
      indirect comparisons showed that there were no significant differences between 
      zibotentan plus docetaxel versus atrasentan plus docetaxel when compared with 
      docetaxel alone or zibotentan versus atrasenta compared with placebo in the 
      improvement of PFS, OS, TTP, and total adverse events. CONCLUSIONS: There were no 
      significant benefits for ET-A receptor antagonists with or without docetaxel in 
      the improvement of PFS, OS, TTP, and overall AEs. And there were no significant 
      differences between zibotentan and atrasentan. Single-agent docetaxel should 
      remain as one of the standard treatments.
FAU - Qi, Ping
AU  - Qi P
AD  - Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou 730030, 
      China; Department of Clinical Laboratory, The Second Hospital of Lanzhou 
      University, Lanzhou 730030, China.
FAU - Chen, Ming
AU  - Chen M
AD  - Department of Urology, GanSu Provincial Hospital of Traditional Chinese Medicine, 
      Lanzhou 730050, China.
FAU - Zhang, Li-xiu
AU  - Zhang LX
AD  - Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou 730030, 
      China.
FAU - Song, Rui-xia
AU  - Song RX
AD  - Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou 730030, 
      China; Key Laboratory of Urological Diseases in Gansu Province, Lanzhou 730030, 
      China.
FAU - He, Zhen-hua
AU  - He ZH
AD  - Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou 730030, 
      China; Department of Neurosurgery, The Second Hospital of Lanzhou University, 
      Lanzhou 730030, China.
FAU - Wang, Zhi-ping
AU  - Wang ZP
AD  - Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou 730030, 
      China; Key Laboratory of Urological Diseases in Gansu Province, Lanzhou 730030, 
      China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150720
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Endothelin A Receptor Antagonists)
RN  - 0 (Pyrrolidines)
RN  - 0 (Taxoids)
RN  - 0 (ZD4054)
RN  - 15H5577CQD (Docetaxel)
RN  - V6D7VK2215 (Atrasentan)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Atrasentan
MH  - Disease-Free Survival
MH  - Docetaxel
MH  - Endothelin A Receptor Antagonists/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy
MH  - Pyrrolidines/administration & dosage/adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Taxoids/adverse effects/therapeutic use
MH  - Treatment Outcome
PMC - PMC4508042
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/07/21 06:00
MHDA- 2016/04/26 06:00
PMCR- 2015/07/20
CRDT- 2015/07/21 06:00
PHST- 2015/05/05 00:00 [received]
PHST- 2015/06/30 00:00 [accepted]
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2016/04/26 06:00 [medline]
PHST- 2015/07/20 00:00 [pmc-release]
AID - PONE-D-15-16577 [pii]
AID - 10.1371/journal.pone.0133803 [doi]
PST - epublish
SO  - PLoS One. 2015 Jul 20;10(7):e0133803. doi: 10.1371/journal.pone.0133803. 
      eCollection 2015.